-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AbLr5zkgW1Ejp2bXLKQO47VKDpnpwNdchQq6RHaHiKyf8gwwxjDJjQmoKkKL9Ke0 dXg8/V/VomGQsytMi6YCeQ== 0001179110-07-002854.txt : 20070205 0001179110-07-002854.hdr.sgml : 20070205 20070205203002 ACCESSION NUMBER: 0001179110-07-002854 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20070205 FILED AS OF DATE: 20070205 DATE AS OF CHANGE: 20070205 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNTA PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: 45 HARTWELL AVE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-274-8200 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jacobson Eric W CENTRAL INDEX KEY: 0001388483 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 07582315 BUSINESS ADDRESS: BUSINESS PHONE: 781-274-8200 MAIL ADDRESS: STREET 1: C/O SYNTA PHARMACEUTICALS CORP. STREET 2: 45 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 3 1 edgar.xml FORM 3 - X0202 3 2007-02-05 0 0001157601 SYNTA PHARMACEUTICALS CORP SNTA 0001388483 Jacobson Eric W C/O SYNTA PHARMACEUTICALS CORP. 45 HARTWELL AVENUE LEXINGTON MA 02421 0 1 0 0 Sr. VP, Research and CMO Common Stock 25000 D Employee Stock Option (Right to Buy) 14.00 2015-04-11 Common Stock 25000 D Employee Stock Option (Right to Buy) 14 2016-02-15 Common Stock 27723 D Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which the number of shares of Common Stock was divided by 4. The option vested as to 25% of the shares on April 11, 2006 and as to an additional 6.25% of the shares on the last day of each calendar quarter thereafter. Reflects a 1-for-4 reverse stock split effected on February 2, 2007 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of Common Stock underlying the option was divided by 4 and (ii) the exercise price of the option was multiplied by 4. The option vests as to 25% of the shares on February 15, 2007 and as to an additional 6.25% of the shares on the last day of each calendar quarter thereafter. /s/ Ann Margaret Eames, Attorney-in-Fact 2007-02-05 EX-24 2 ex24poaejacobson.txt POWER OF ATTORNEY POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Safi R. Bahcall, Ph.D., the President and Chief Executive Officer of Synta Pharmaceuticals Corp. (the "Company"), Keith S. Ehrlich, the Vice President, Finance and Administration, Chief Financial Officer of the Company, and Wendy E. Rieder, the Vice President, Intellectual Property and Legal Affairs, General Counsel of the Company, and Brian Keane, Daniel T. Kajunski, and Ann Margaret Eames of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, forms and authentication documents for EDGAR Filing Access; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and authentication documents; (3) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (4) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in- fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 27th day of January 2007. /s/ Eric W. Jacobson Signature Eric W. Jacobson Print Name -----END PRIVACY-ENHANCED MESSAGE-----